Praxis Precision Medicines Inc.
Praxis Precision Medicines Announces Positive Results from Phase 2a Study of PRAX-628 in Epilepsy
Summary
On March 26, 2024, Praxis Precision Medicines, Inc. reported positive results from its Phase 2a proof of concept study evaluating PRAX-628 in epilepsy patients with photo paroxysmal response (PPR). The study showed a complete response rate of 88% and a total response rate of 100% in the combined cohort. Safety results were consistent with prior studies, and the Company plans to initiate an efficacy study in focal onset epilepsy in the second half of 2024.
Profitelligence Alerts
Get alerts for PRAX
Be first to know when Praxis Precision Medicines Inc. files with the SEC.
Filing Categories
Advertisement
About Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc. operates within the biopharmaceutical sector, focusing on the development of treatments for central nervous system (CNS) disorders. The company's primary objective is to address unmet medical needs by leveraging their extensive research in genetics, the neurobiology of CNS disorders, and translational science. Praxis Precision Medicines is rapidly carving out a niche in the healthcare field by targeting illnesses such as epilepsy, movement disorders, and psychiatric conditions, which impact millions of individuals globally. Their innovative pipeline includes a variety of therapeutic candidates designed to modulate specific neural pathways that are believed to be core to CNS dysregulation. As an emerging leader in the biopharma industry, Praxis Precision Medicines plays a crucial role in advancing CNS treatment paradigms, working to improve quality of life for patients and expand the possibilities of personalized medicine through cutting-edge science.
Official SEC Documents
Advertisement